Background: Micronutrients, an umbrella term used to collectively describe vitamins and trace elements, are essential components of nutrition. Those requiring alternative forms of nutrition support are dependent on the prescribed nutrition regimen for their micronutrient provision. The purpose of this paper is to assist clinicians to bridge the gap between the available guidelines' recommendations and their practical application in the provision of micronutrients via the parenteral route to adult patients. Methods: Based on the available evidenced-based literature and existing guidelines, a panel of multidisciplinary healthcare professionals with significant experience in the provision of parenteral nutrition (PN) and intravenous micronutrients developed this international consensus paper. Results: The paper addresses 14 clinically relevant questions regarding the importance and use of micronutrients in various clinical conditions. Practical orientation on how micronutrients should be prescribed, administered, and monitored is provided. Conclusion: Micronutrients are a critical component to nutrition provision and PN provided without them pose a considerable risk to nutrition status. Obstacles to their daily provision-including voluntary omission, partial provision, and supply issues-must be overcome to allow safe and responsible nutrition practice. (JPEN J Parenter Enteral Nutr. 2019;43(suppl 1):S5-S23)
Introduction and Purpose of the Paper
Micronutrients-that is, vitamins and trace elements (TEs)-are essential components of nutrition. While they are provided by a varied diet to the general population, those requiring alternative forms of nutrition support are dependent on the prescribed nutrition regimen for their micronutrient provision.
Although the importance of micronutrients has been known for decades, the use of vitamin and TE admixtures with parenteral nutrition (PN) is often not a routine process, because of the misconception that PN providing macronutrients is "total." The conviction prevails that despite obvious malabsorption in short bowel patients, diet and oral micronutrient supplements can meet the requirements of patients who are able to eat, but nevertheless depend on PN. However, this can be partly true only if the proximal small bowel is still functionally active. Additionally, the lack of reliable assessment for the clinical status of several micronutrients, access to these laboratory measurements, and standardization of techniques in quantifying micronutrients make it difficult in most settings to monitor micronutrient levels. Costs and difficulties obtaining remuneration for micronutrient provision, as administrators have trouble paying for what they regard as a "supplement," can also be a factor as well as a lack of awareness about the importance of micronutrients in metabolism and the need to prescribe them along with PN formulations.
These are some of the reasons a number of multidisciplinary nutrition societies have developed guidelines to help clinicians navigate the issues around the prescription, administration, and monitoring of micronutrients in both short-term (<3-4 weeks) and long-term (ࣙ4 weeks) PN. 1 However, a discrepancy between the recommendations in these guidelines and current clinical practice is acknowledged. Also, when guidelines formulated for specific locations are attempted to be implemented outside of the intended region, it can result in confusion (e.g., guidelines quoting specific products that are often not available outside of that region or the use of different units of measurement between regions).
The purpose of this international consensus paper is to assist clinicians to bridge the gap between the available guidelines' recommendations and their practical application in the provision of micronutrients via the parenteral route to adult patients. Therefore, the primary intended audience is clinicians prescribing PN to adults, and secondarily the organizations and health services in which PN is being utilized to support safe PN practice. It is hoped that in making clear the practice application of the guidelines, this expert consensus paper will assist in guiding international practices in PN provision to the evidence-based guidelines available, and to serve as a platform for clinicians, organizations, and regions to advocate for access to the resources required to administer PN safely. This paper is not intended to provide a comprehensive systematic review of all aspects of intravenous (IV) micronutrients, although where clinically relevant, micronutrient provision independent of PN may be addressed. Where more in-depth relevant clinical content is out of scope of this paper, readers will be directed to more comprehensive references to obtain further information.
Methodology
A panel of multidisciplinary healthcare professionals recognized as micronutrient experts were invited to participate in the development of an international consensus statement. Initial face-to-face meetings were held for various regional clusters (North America, Latin America, Europe and Africa, and Asia Pacific), where the scope and planning of the statement were discussed. The individual inputs incorporate literature searches through MEDLINE (accessed via PubMed) and personal databases. Thereafter, the panel functioned remotely through the facilitation of a steering committee (RB, KS, EO), which designed and compiled the framework of the document. The final paper was compiled based on input received from all members. It was circulated for comments and consensus within the group prior to finalization under the guidance of the steering committee.
The views presented here reflect the interpretation of the literature and existing guidelines by clinicians with significant experience in the provision of PN in a range of contexts from different geographic locations around the world. The information presented will be limited to adult patients due to the differences in physiology, metabolism, requirements, and nutrition goals in the pediatric population. The following micronutrients have been addressed: fatsoluble (vitamins A, D, E, K) and water-soluble (vitamins B and C) vitamins, and TEs copper (Cu), iodine (I), iron (Fe), selenium (Se), zinc (Zn), chromium (Cr), manganese (Mn), and molybdenum (Mo). Fluoride is available in some markets for addition to PN formulations, however the majority of patients meet their requirements through fluoridated beverages (including water). 2 Due to fluoride not being a routine addition to PN, it has not been addressed within this review.
Terminology
Hereafter, the word supplementation will be used when the aim is to achieve supra-normal levels, including pharmaconutrition attempts. Complementation will be used to indicate the delivery of micronutrients to cover basal needs in case of low macrosubstrate intakes (e.g., to complete enteral feeds or PN). Repletion will be used when deficiency or losses are identified and the administration aims at restoring a normal status, and only restoring gaps ( Figure 1 ). Dietary recommended intakes (DRIs) are referred to throughout this document as a reference point from which to understand inadequate micronutrient intake, or as an arbitrary indication of physiological requirements where clear data on IV micronutrient requirements is lacking. DRIs have been developed as recommendations for oral or enteral requirements in healthy populations, and as such their application to acutely or chronically unwell patients requiring IV micronutrient supplementation should be considered in light of the overall clinical assessment. The doses used in PN, and considered to cover basal needs in the majority of patients, will be called parenteral nutrition recommended doses (PN-RD).
Q1: Why are Micronutrients Important?

Recommendation
Micronutrients are essential for the metabolism and utilization of macronutrients and affect virtually every enzyme system in the body. As such, they constitute a crucial component of nutrition therapy and should be delivered in the recommended amounts daily.
Rationale
Micronutrients play important roles in intermediary metabolism through their function as cofactors in enzymes and as coenzymes, antioxidant systems and gene transcription. Micronutrients act in concert with one another. PN provided without proportionate micronutrients over time will result in the development of deficiency, metabolic dysfunction, and in some cases, death. 
Q2: What is the History of Micronutrients in Parenteral Nutrition?
The awareness about micronutrient needs in PN goes back to the 1970s. PN was developed in the 1950s and early 1960s, 5 as a combination of three distinct components: amino acids, glucose, and finally lipid emulsions in 1961 (no mention of micronutrients). The initial amino acid solutions were prepared by acid hydrolysis of so-called "highquality proteins" such as casein. Later, the preparations were purified by dialysis, until the synthesis in 1964 of crystalline amino acids. Due to the purification process, the amino acid solutions became deficient in TEs and vitamins, which resulted in clinical deficiencies developing in patients dependent on prolonged PN.
Trace elements
Kay et al. published a case series of 37 adult patients in 1976, in whom Zn deficiency was diagnosed after 3 weeks of PN. 6 The combination of diarrhea, mental depression, paranasal, oral and peri-oral dermatitis, and alopecia was called the Zn deficiency syndrome. These symptoms were reversed by the administration of Zn. 6 A case of reversible Cr deficiency presenting with peripheral neuropathy and severe glucose intolerance after 5 years of PN was published. All symptoms resolved with Cr administration. 7 In 1977, Jacobson et al. studied the balances of 20 TEs during PN in four male patients who were receiving additional Cu, fluoride (F), Fe, I, Mn, and Zn. 8 The authors observed unintentional administration of several nonprescribed TEs due to contamination of the solutions. The authors also observed a decline of the serum concentrations of 13 TEs (including Cu, Fe, Mo, Se, and Zn), corresponding to the negative balance values. Based on their findings, the authors wrote the first recommendation to systematically administer TEs with PN. 9 In 1979, the American Medical Association published the first guidelines for essential TE provision during PN. 10 
Vitamins
While the FDA had validated an adult formulation for nine water-soluble and four lipid-soluble vitamins in 1979, 11 awareness about potential vitamin deficiency during PN came later, with the diagnosis of cardiac failure with lactic acidosis in patients after 4 weeks of PN without vitamin supplementation. 12 Awareness about deficiencies occurred simultaneously in the United States and Europe. 13 Cases of Wernicke's encephalopathy were described. 14 Labadarios et al. showed that several vitamins exhibited a deficiency pattern after prolonged PN despite the administration of available IV multivitamin (MV) products. 15 Vitamins of the B group, C, A, and D were low in 40-80% of patients.
In 2009, an American workshop analyzed the available vitamin and TE solutions. 16 While the product contents were considered sufficient for stable patients, concerns were formulated as to the unavailability of separate vitamin and TE solutions to face increased needs. The reality of TE and vitamin administration in clinical settings was questioned. 
Rationale
In cases where PN is not indicated, or in cases where it is not the sole route of nutrition provision, alternative enteral or oral micronutrient administration options may exist. It is, however, beyond the scope of this paper to discuss enteral therapy. For this purpose, the discussion will be focused on IV administration in the context of PN, or in cases where enteral routes are not sufficient or reliable to deliver the intended doses.
Conditions in the ICU that have been associated with micronutrient depletion include major burns, 21 losses from surgical or traumatic wounds, 22 gastrointestinal (GI) fistulae, 22 losses due to GI diseases or resections resulting in decreased absorptive area, 4, 20 and continuous renal replacement therapy (CRRT). 3, 21, 23 Unbalanced and insufficient administration during medical nutrition therapy throughout the critical care journey places patients at greater risk during these situations. 4 Various deleterious consequences have been linked to micronutrient deficiencies, including poor wound healing, muscle weakness, inadequate immune response, and organ dysfunction. 4, 24 While the critically ill population represents a heterogeneous group of clinical pathologies, commonly reported micronutrients of concern include Zn, Fe, and Se 4 ( Tables 1-3) . Patients with potential preexisting vulnerability/malnutrition should be identified and treated early in the admission, and all patients receiving PN support in the ICU should be provided daily IV MV and MTE preparations to prevent the development of micronutrient deficiency. 19, 20, 24 The conditions qualified as insufficient intakes in Table 1 may justify the temporary administration of complemental IV micronutrients at doses sufficient to cover basal metabolic PN-RD needs during the acute phase of disease, that is, the first 5-7 days, when EN is not yet at full requirements, 25 especially in those patients with prior poor nutrition status or suspected GI malabsorption.
For critically ill patients with specific identified micronutrient deficiency risks, additional prescription may need to be considered and the use of higher doses of IV micronutrients, either as part of PN provision or as a standalone intervention, may be warranted.
The micronutrient interventions in conditions with increased oxidative stress affecting endothelial function and other inflammation-related pathologies using high-dose single micronutrients cannot be considered as nutrition and are categorized as pharmaconutrition 26 (please refer to Q5 and Q6). 
Q4
Rationale
Critical illness represents an extreme form of metabolic stress, which exhibits a phased response (ebb followed by flow phase). 27 Physiologically the metabolic changes associated with metabolic stress are referred to as the acute phase response. 106 Very high dose IV doses of Selenium (up to 100 times the DRI) have been hypothesized to improve antioxidant function during critical illness; however, this has not been associated with significant clinical benefit. 107 The case for high-dose IV ascorbic acid (200 mg/kg/24 h) in septic shock during the first 72 h, however, seems promising, 108 and phase III trials are in completion phase.
Major burns in resuscitation phase
High-dose ascorbic acid (66 mg/kg per hour for 24 h) during the first 24 h has been associated with reduction of fluids required for stabilization. 109 
Insufficient enteral intakes in inflammatory patients
In critically ill enteral nutrition (EN) is introduced progressively during the first days in the ICU. Thereafter, EN is frequently interrupted for procedures. This results in nutrition goals including micronutrient needs not being covered.
With the majority of EN solutions, micronutrient DRI requirements are only met when 1-1.5 L of product (±1500 kcal) is administered. 21, 110 Further, enteral absorption is variable, particularly during critical illness and in conditions that alter gut function (such as intestinal failure). Finally, some patients have energy needs less than 1500 kcal/day, which exposes them to less than DRI intakes.
Micronutrient requirements are modified by acute disease due to increased losses in some pathologies, decreased intake, and increased usage to facilitate tissue repair. The associated acute phase response results in redistribution of the micronutrients due to the release of pro-inflammatory cytokines. 4, 20, 24, [27] [28] [29] This results in altered serum concentrations and decreased total body reserve in case of loss. 4 It is important to determine the cause of decreased circulating levels in order to correctly treat the situation.
In response to increased cytokine levels, vitamins A, C, E, and D will decrease below the lower reference values, and so will Fe, Se, Zn, 4 Mn, and Mo. But low values do not necessarily indicate deficiency. 29, 30 This redistribution and increased utilization (e.g., vitamin C) may represent a beneficial adaptive response to critical illness. 31 Under the same circumstances, Cu and Cr will increase, sometimes to values superior to the upper reference value.
The B vitamin family is little affected by inflammation. Therefore, and provided they have not been administered prior to blood testing, serum levels of vitamins B 1 , B 2 , and B 12 constitute an accurate reflection of deficiency, since they are not affected by inflammation. 4 The impact of metabolic stress and inflammation on status is depicted in Table 2 .
It is acknowledged that it is very difficult to differentiate between a true micronutrient deficiency and an inflammation-induced low value. This is an area of active research and different models have been proposed, which include adjusting micronutrient concentration for albumin status, 32 plasma retinol concentration, 30, 33 and using various regression-correction models to account for inflammation. 34 Currently, there is no universal approach to account for inflammation when determining micronutrient status. 35 Micronutrient concentrations should always be determined in conjunction with an indicator of inflammatory status, 19, 20, 30, 36 such as CRP. Inflammation may be classified minor (CRP < 10 mg/L), moderate (CRP between 11-80 mg/L), and major (CRP > 80 mg/L). 30 In pathologies with excessive losses (Table 1 ) and simultaneous inflammatory response, the interpretation is complicated by the latter. From trials in pathologies such as major burns, multiple trauma, and complex cardiac surgery, which have used other indicators such as plasma glutathione peroxidase concentrations to interpret the results, deficiency state should only be considered in the presence of micronutrient serum values of more than 20% below the lowest reference value. 25 In addition such values should be Table 2 . Impact of metabolic stress on micronutrient status.
Micronutrient Effect of acute phase response
Copper r Increased serum copper levels. 19, 27, 28 Pro-inflammatory cytokines stimulate the acute phase response. More copper is needed for increased ceruloplasmin synthesis, which, in turn, is required for iron transport. r Serum copper levels should be interpreted in the context of inflammatory markers (e.g., CRP). 19 Iron r Decreased serum iron levels to ensure that less circulatory iron is available for bacteria to thrive on and to decrease oxidative damage to cells. 4, 19, 24, 27, 28, 30, 35 r Increased ferritin (store) levels. 19, 27, 28, 30, 35, 61 r Serum iron levels should be interpreted in the context of inflammatory markers (e.g., CRP).
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Selenium r Decreased serum levels 4, 19, 24, 27, 28, 30, 36, 59 in proportion to the magnitude of the inflammatory response and also due to increased urinary losses. r Serum selenium levels should be interpreted in the context of inflammatory markers (e.g., CRP). 19 r Selenium concentrations should be interpreted with caution in the presence of moderate to intense inflammation. 28, 29 In the latter case and in the absence of glutathione peroxidase determination, only very low values of selenium (<80% of reference value) should be considered as potentially reflecting deficiency. 25 
Zinc
r Initial serum increase due to tissue damage that results in excessive zinc release. 27 r Followed by decreased serum levels due to increased losses (skin, urine and stool) and decreased serum albumin levels. Albumin is a negative acute phase protein and since zinc is bound to albumin for transport, decreased albumin levels will result in less available zinc. 4, 19, 24, [27] [28] [29] [30] 36, 59 r Redistribution of zinc also results in an increased accumulation of zinc in the liver where it acts as cofactor for acute phase protein (APP) synthesis. r Serum zinc levels should be interpreted in the context of inflammatory markers (e.g., CRP). 19, 29 r A reliable zinc deficiency interpretation can only be made if serum CRP levels are <20 mg/L. 28, 29 Very low levels <50% below lowest reference values should always be considered as suspect of deficiency. See Question 4 for interpretation. Vitamins-general r Decreased serum levels due to increased requirements (which could be due to increased metabolic rate and also because vitamins are used for biochemical functions during the acute phase response, e.g., protein metabolism), increased catabolism, malabsorption, increased urinary losses and potential drug interactions. 27 r May return to normal serum levels after infection resolves without any treatment. For instance, vitamin A is bound to retinol-binding protein (RBP) for transport. RBP is a negative APP and therefore status will normalize after infection clears and hence vitamin A levels will improve. 27 Vitamin A r Vitamin A decreases during the acute phase because RBP acts as a negative acute phase protein. 27, 28, 36 Vitamin B 1 (thiamine)
r Increased requirements for vitamin B 1 may be needed during periods of increased metabolic stress and increased dietary carbohydrate provision. 20 r Serum levels not affected by periods of inflammation. 4 Vitamin B 2 r Serum levels not affected by periods of inflammation. 4 Vitamin B 6 r A decrease in serum vitamin B 6 is seen with only a slight increase in CRP ( 5-10 mg/L); 29,36 therefore caution should be taken when interpreting true deficiency. Vitamin B 12 r Serum levels not affected by periods of inflammation. 4 Vitamin C r A decrease in serum ascorbic acid 28, 30, 36 is seen with only a slight increase in CRP ( 5-10 mg/L). 29 r Therefore caution should be taken when interpreting true deficiency. r Decreased plasma concentrations are seen within 24 h postacute injury.
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Vitamin D r A decrease in serum 25(OH)-vitamin D is seen with only a slight increase in CRP ( 5-10 mg/L), 29, 30, 36 therefore caution should be taken when interpreting true deficiency. Vitamin E r Circulating vitamin E declines modestly during inflammation, 20, 28, 30, 36 without reflecting deficiency. 29 repeated to observe trends, as the isolated value is of limited value.
Further, the interpretation of these results and subsequent action needs to differ for acute or chronic conditions. Acute care. In the case of an acute illness, any deficiency in micronutrient concentrations needs to be corrected in an attempt to improve clinical outcomes. Correction is necessary due to the harmful effects of the micronutrient deficiencies on antioxidant defense mechanisms, metabolic pathways, and general immune pathways. 37, 38 Longer term home parenteral nutrition (HPN). The concept is around monitoring of nutrition status and identifying 49 Iron r Despite iron deficiency anemia being commonly observed during critical illness, this is multifactorial and may represent a beneficial adaptive change during critical illness. r There are presently no recommendations to manage iron deficiency with iron as a monotherapy. 99, 113 Selenium r Selenium supplementation has been studied in sepsis and septic shock with mixed findings, and high-dose, supra-physiological supplementation is not presently recommended in critically ill patients. 3, 114 r Negative selenium balances have been demonstrated in CRRT, 49, 112 with losses of up to 1 μmol/24 h of CRRT reported. 49 Zinc r Zinc is recognized to be a vulnerable trace element in the critically ill that should be monitored and replaced if underlying deficiency or high risk of developing a deficiency is suspected. 115 r However, no recommendations currently exist to guide optimal zinc dosing in the critically ill patients (IV or otherwise). 116 r For acute renal failure requiring CRRT, an additional daily IV multi-TE supplement such as used for PN is recommended. 117 Mixed antioxidant vitamins (A,C,E)
r Supplemental vitamin and trace element combinations (Zn, Se, vitamins A, C, E, N-acetylcysteine, provided via EN or IV or combination) are not recommended in critically ill patients. 114 r In major burns, combination of Cu, Se, Zn, vitamin C in doses 5-10 times the PN-RD added to the standard multi-micronutrients are provided IV during the first 2-3 weeks and result in normalization of antioxidant function. 39 Vitamin B 1 (thiamin)
r Thiamin is emerging as an increasingly important vitamin in the management of sepsis. Normalizing thiamin levels during septic shock may reduce mortality and reduce progression to renal replacement therapies, although these results require validation. 118 r High thiamin losses have been demonstrated with CRRT and thiamin supplementation should be considered in this patient group to avoid the development of deficiency. 21, 49, 112 r Refeeding syndrome may be seen in the ICU, particularly with the high rates of malnutrition observed in the critically ill patients. Depending on refeeding risk, IV thiamin replacement prior to or together with commencement of feeding is recommended in refeeding prevention and treatment. 119 r MV admixtures contain the DRI for thiamin, but this amount may be insufficient with a high dextrose load, leading to iatrogenic deficiency states. Considering its low risks, a liberal amount of thiamin should be administered in critical care practice at daily dosages of 300 mg IV for at-risk patients, and 100 mg IV in all other patients, during the first 48 h of ICU admission. 118 Vitamin B 6 r Patients with acute renal failure requiring CRRT should receive 100 mg vitamin B 6 IV daily for 3-5 days. 117 r Monitor serum levels. Vitamin C r Vitamin C may be beneficial in times of oxidative stress 120 and requirements are acknowledged to increase during critical illness. 118 r Pharmacological doses may be of benefit in the early stages of critical illness, 118 however these results require validation. 114 r Vitamin C replacement may be of benefit to reverse depletion demonstrated during cardiopulmonary bypass. 121 r Monitoring of plasma concentrations is recommended in patients requiring PN for more 6 months or more. 38 r The risk of nephrolithiasis should be monitored in long-term HPN patients. 63 Vitamin D r Vitamin D levels are recognized to be commonly low in critically ill populations and a predictor of outcome. 114, 118, 122 r Vitamin D is ineffective in the acute setting. The 1,25 hydroxy form is needed when liver and renal functions are suboptimal. 123 Until the results of on-going trials are available and accepted (VIOLET study, NCT 03096314 and VITDALIZE study, NCT 031188796), the routine administration of additional Vitamin D (by oral or intramuscular route) for patients on short-term PN cannot be justified. 124 r It should be noted, however, that some papers describing lack of benefit of vitamin D in critically ill patients may be flawed in design as the levels were obtained after resuscitation. 125 developing deficiency or toxicity states assumed to be at least in part contributed to (and therefore ameliorated by modifying) the composition of the home parenteral nutrition (HPN) formulation. In these cases, knowledge of CRP with respect to micronutrient interpretation is essential to avoid inadvertently modifying long-term provision without due cause, and which may unnecessarily expose the patient to harm (i.e., reducing levels or increasing levels that are artificially elevated or lowered by an inflammatory response). Therefore, for chronic illness, correction of a suspected micronutrient deficiency in the presence of infection should be deferred until the inflammation has been resolved. The micronutrient status needs to be repeated and if still deficient, repletion is recommended to restore concentrations. 20 Monitoring during long-term PN is, nevertheless, needed at intervals as the MV and TE products are not weight or metabolism adapted: "one size fits all" may indeed result in inappropriate individual therapy.
Finally a word of caution regarding laboratory blood determinations -clinicians should be aware that these values only reflect fluxes between compartments and not intracellular concentrations or true body pools. 
Q5: Which Intravenous Micronutrients
Rationale
Burn injuries result in homeostatic changes that are proportional to the size of the burn injury. 39 Resulting hypermetabolism and catabolism increase the nutrition needs (energy, protein, and micronutrients), while oxidative stress and large exudate losses from the burn wounds drive major fluid and TE losses. It is therefore vital that burns patients receive additional micronutrients, even if not on PN provision. 39 For small burns (defined as those <20% BSA), micronutrient maintenance doses (as defined by DRI or local equivalent indicating daily balanced needs) are generally sufficient. 40 For major burns (>20% BSA), systematic micronutrient repletion is recommended from admission for 2-3 weeks until wound closure. 39 Early resuscitation phase. High-dose vitamin C has been identified as having a potential role in reducing fluid resuscitation requirements through stabilizing the endothelial membrane against increased permeability 41 (Table 1) . Vitamin C can be safely used without an increased risk of renal failure. 42 This is a pharmacological intervention.
Wound healing phase. Micronutrient status is particularly vulnerable during the active healing phases of burns-this is particularly true for micronutrients involved in antioxidant pathways. 43, 44 Large TE losses (particularly of Cu, Se, and Zn) in wound exudates have been demonstrated during the first week postinjury, 37, 45 while randomized controlled trials have shown that active repletion of these TEs with doses compensating losses reduces infectious complications, improves skin graft take, and reduces length of ICU stay. 46, 47 Proposed Se repletion doses of 500-700 μg/day IV, Cu 4 mg/day IV, and Zn 40 mg/day IV have been shown to be safe for 2-3 weeks (burns >20%) and do not require specific blood concentration monitoring.
Additional considerations during this phase include the impact of other supportive therapies. CRRT of longer than 2 weeks duration has been shown to increase the risk of Cu depletion and warrants regular Cu monitoring (ideally weekly) 48 due to effluent losses 49 in institutions where timely laboratory support is possible 48 (see Tables 1 and 2 for other micronutrient considerations of CRRT).
In 1986, Boosalis et al. were the first to show that the Se status of major burn patients was severely compromised. 43 In 1991, Cunningham et al. showed severe Cu deficiency in extensively burned children. 44 Balance studies conducted in Lausanne showed that previous reports on Cu, Se, and Zn deficiencies in burns settings 50 were the result of early large exudative losses of TEs during the first week postinjury, particularly for Cu, Zn, 50 and Se. 37, 45 Recently, the Lausanne group published a dose-finding study conducted in 139 patients with burns injuries on 35% BSA showing that their actual IV repletion protocol was safe and normalized Cu and Zn concentrations. 51 Despite the oxidative stress present in major burns, Se doses of 845 μg/day delivered until 2016 resulted in supra-normal Se concentrations, suggesting a reduction to 500-700 μg/day. Nevertheless, in case of CRRT exceeding 2 weeks in major burns, the additional high risk of Cu depletion due to prolonged effluent losses 49 requires weekly Cu blood monitoring. 48 Copper deficiency, in the presence of inflammation where increased levels are normally found, 27, 28 requires immediate IV corrective action.
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Recovery/rehabilitation phase. Vitamin D deficiency has been demonstrated in major burns and is caused by skin damage and absence of sun exposure. 52 The standard DRI doses are insufficient to cover the needs and maintain circulating Vitamin D within normal ranges. 53 However, a systematic addition of supplemental doses has not been recommended so far. 
Q6: When Should Intravenous
Rationale
A thorough knowledge of the GIT absorption sites for the various micronutrients is essential to predict potential deficiencies due to malabsorption post GIT surgery. Figure 2 depicts the most common absorption sites for micronutrients, and Table 4 summarizes the most common micronutrient deficiencies that can develop post GIT surgery due to the area resected. Complications following surgery could also impact micronutrient losses. Patients developing enterocutaneous fistulae can have excessive losses of Zn and Se, 4, 19 18 zinc, and iron due to losses 19 whereas patients presenting with chyle leaks could become Se deficient due to increased losses. 54 Zinc requirements are increased in intestinal and biliary losses, including fistulae, severe diarrhea, and chyle leaks, as well as sepsis, hypercatabolic states, and burns, where additional supplementation is required. 55 Replacement of about 12 mg of Zn (IV) per liter of GIT losses in patients with fistulae, stomas, and diarrhea has been recommended. 22 Additional Zn, over and above the daily recommended parenteral doses, may be added to short-term IV infusions in at-risk patients; however, it must also be noted that there is inadequate published information on the compatibility between injectable Zn solutions and other IV admixtures. As Zn is readily absorbed in the duodenum, the enteral route may be used if this part of the intestine is accessible and functional. Ideally monitoring of serum Zn levels should be undertaken every second week, 22 however this needs to be assessed against the inflammation present in surgical complications as confounding factor for interpretation of Zn levels. Nevertheless, persisting low or decreasing levels would be indicative of insufficient repletion doses. 29 Vitamin K deficiency may be unrecognized, as the laboratory test for coagulation (prothombin time, international normalized ratio) may not be sensitive enough to detect subclinical deficiency states, which can become unmasked after surgical procedures or resuscitation. Antibiotics often alter the intestinal flora and potentially decrease the bacterial production of vitamin K. If the patient is also nil per os, the usual oral source of vitamin K is not available. Some MV preparations may contain insufficient amounts of vitamin K or none at all. Small amounts of vitamin K, although highly variable with the product being used, are available from fat emulsions, but cannot be relied upon. The prudent clinician should consider additional parenteral vitamin K (intramuscular or added to PN) whenever the clinical situation demands it, especially prior to elective surgery, irrespective of laboratory tests. A weekly dose of 250 -400 μg is recommended if the additive does not contain vitamin K. 56, 57 Selenium deficiency may occur with GIT, bile or chyle losses or when Se is not added to PN. Chylous fistulae, for which PN is often required, result in micronutrient losses due to the large volumes of protein-rich fluid being lost. Selenium deficiency secondary to these losses has been reported and it is highly likely that other TEs are also lost. 54 Selenium is not a component of MTE admixtures in some countries. However, it is an important essential TE, with major antioxidant functions. It is recommended that patients with small bowel resection, inflammatory bowel disease, or other intestinal disorders should have their Se level checked prior to starting PN and every 3 months if deficiency is found. 58 When Se deficiency is suspected based on clinical presentation or laboratory tests, clinicians should first make sure that the MTE admixture does indeed contain Se. Pharmacologic doses of Se for specific conditions have been studied, and shown to be safe, but is not the standard of practice. 59 Bariatric surgery, and especially malabsorptive procedures, can result in many micronutrient deficiencies. This includes fat-soluble vitamins (A, D, E, K), watersoluble vitamins (especially vitamins B 1 , B 6 , and B 12 ), and TEs (Fe, Cu, and Zn). 4 It is recommended that micronutrient status should be determined prior to and after bariatric surgery. 60 This should begin at least 1 month before the procedure and continue lifelong thereafter. 60 Pre-and postbariatric surgery nutrient screening and supplementation recommendations to prevent and treat micronutrient deficiencies are available. 60, 61 It is clear that surgery, inclusive of bariatric surgery, could have direct consequences on micronutrient status and additional micronutrient requirements are needed in cases of wound healing. However, in cases of a functional gut, micronutrient correction can be done via the oral or enteral route. In general, an adequate supply of micronutrients is considered essential for any surgical patient on long-term PN. 62 The route of supplementation will be dictated by the adequate functioning of the GIT.
Q7: What are the Roles and Importance of Micronutrients in Home Parenteral Nutrition?
Recommendation Micronutrients provided as part of an individually prescribed HPN formulation are essential to patients with long-term HPN requirements and may represent the only reliable source of micronutrient provision and replacement. Monitoring of micronutrient status should be overseen by a team with expertise in HPN/intestinal failure management.
Rationale
Micronutrient status of HPN patients has traditionally been a focus of concern, 63 and levels continue to be demonstrated to be vulnerable. 64 Therefore, micronutrients need to be seen as an essential component of HPN provision, 19, 20, 65 and in some cases may be the only reliable source of micronutrient provision in this population. Unless otherwise clinically indicated, they should be provided with each bag of HPN. 20 Due to the long-term nature of HPN provision, monitoring of micronutrient status is required at baseline and at 6-12 month frequency 19, 20, 65 to detect deficiency and/or toxicity states. The frequency can vary according to changes in clinical status and micronutrient prescription. 20 Individualized prescriptions and supplementation courses need to be modified according to micronutrient levels and their trends as well as the clinical situation. 19, 20, 65 In HPN patients, vitamin D levels should be monitored every 12 months and corrected accordingly (IM, separate IV infusion or higher PN dose). 20 Bone mineral density measurements should also be done annually in long-term HPN patients. 66 Micronutrient prescription for HPN patients, as all aspects of HPN management, should be overseen by a multidisciplinary nutrition support team (NST) with skills and experience in managing intestinal failure and HPN. 65 Micronutrient prescriptions for HPN patients should be individually tailored in response to monitoring and clinical changes throughout the duration of a patient's HPN journey. 19, 20, 65 Factors requiring consideration include: r vulnerable micronutrient status at baseline/HPN commencement, r micronutrient losses or malabsorption due to anatomical considerations (e.g., fistulae and altered GIT anatomy) or increased physiological turnover due to concurrent comorbid conditions (e.g., for wound healing, chronic inflammation, etc.), r alterations to micronutrient excretion that may require reduced doses or omission of some micronutrient (e.g., such as may occur in cholestasis, chronic kidney injury, etc.), and r the degree to which oral or enteral intake may contribute to the partial provision of some micronutrients, and the changes that may occur in this over time in the setting of natural or pharmacologically facilitated intestinal adaptation. 
Q8: How should Micronutrients be Provided
Rationale
Issues of compatibility and stability must always be considered when providing micronutrients concurrently with PN formulations. By definition ready-to-use PN formulations contain no micronutrients, except in case of compounding, and the latter implies limited stability of the PN formulation. It is essential that micronutrients be administered daily with PN: failure to do so may affect substrate bioavailability, metabolic function, and clinical efficacy. [68] [69] [70] [71] Formulations of micronutrient admixtures vary by region, and these differences may impact chemical stability and subsequently mandate-specific methods by which individual combinations are added to PN. 19, 20 It is, therefore, essential that clinicians and technicians involved with this process have knowledge about the dose, incompatibilities, stability, and skill to administer micronutrients 67 in accordance with the practices appropriate to their location.
In the absence of strong evidence in the literature comparing the efficacy of different methods of micronutrient delivery in conjunction with PN formulations, decisions of how best to administer IV micronutrients are in practice based on organizational policy and/or facility capabilities. Common options for micronutrient provision include: r incorporation into PN formulations at the time of initial compounding (commercial facilities, hospital pharmacy); r addition to individually compounded or commercially available ready-to-use PN formulations closer to the time of provision under sterile conditions (commercial facilities, hospital pharmacy); r micronutrient provision separate to PN formulation, but within the same 24 h period, such as through side lines during PN infusion or prior to the commencement of PN provision. In these cases, micronutrients should ideally be delivered over the maximum time period recommended and in accordance with the administration recommendations provided by the manufacturer (hospital pharmacy, ward level), r micronutrients can be given via central or peripheral veins. Concentrated multiple TE admixtures must be diluted appropriately and administered slowly and never given as bolus administration. The manufacturer's directions for dilution and administration and compatibility with other components must be followed.
Various situations of micronutrient losses associated with PN delivery have been reported. Inadequate micronutrient provision may occur through the incomplete infusion of the full bag of PN to which the micronutrients have been added. A further means of micronutrient activity loss of photosensitive micronutrients (vitamins A, C, and E) may come through photodegradation through contact of UV light. 72 If sunlight exposure is a consideration, for example, ambulatory patients receiving PN as inpatients or home PN patients, there is the potential for detectable loss of vitamins A and C from the infusion 72, 73 and light protective coverings can be used during infusions to avoid nutrient losses. 20 This is, however, not a routine practice in the hospital environment. Iodine may be a required PN supplement due to the replacement of iodine-containing disinfectants that might result in iodine deficiency in long-term PN patients, who do not have a functional proximal small bowel and are not able to consume sufficient food orally. It might be prudent to test thyroid function periodically in these cases. 74 When micronutrients are added to the PN formulation prior to infusion, in-bag losses of vitamin activity due to oxidation and interactions must be considered. Varying recommendations exist as to how to manage this, which range from addition of IV micronutrients to PN formulations soon before infusion to infusing TE and vitamin components separately to minimize losses. 63 However, further research is required to provide clear evidence-based guidance regarding this.
Inadvertent TE contamination from individual PN components has historically been considered as an additional source of TEs in PN formulations above MTE provision. However, it is unclear to what degree TE contamination patterns have changed with the evolution of storage and handling practices of PN and micronutrient components in recent decades. 20 Manufacturers of individual PN components should carefully monitor and describe TE contamination in their products. Maximum levels of TE contaminants should be included in all PN product labeling. 71, [75] [76] [77] Irrespective of the methods utilized, the establishment of regulations and handling standards for pharmacy and healthcare services involved with PN provision are essential to safeguard sterility of introducing micronutrient to PN formulations, as well as stability and compatibility considerations due to the high-risk nature of PN as a nutrition intervention. 67 These standards should be guided by Good Pharmaceutical Manufacturing Practice 78 and include specifications regarding the characteristics of the physical areas, equipment, and the knowledge and skills of the personnel who make the mixtures for PN. The standards should also be updated periodically. 79 For patients with longer term PN requirements, such as those requiring HPN who may have some residual gut function, oral or enteral supplementation may be feasible depending on their remaining anatomy and other clinical factors. The risk of not meeting requirements is therefore greater via the EN route, 24 and IV options should be favored unless evidence of integration of oral/enteral supplementation can be demonstrated.
Q9: What are the Challenges in Administering Intravenous Micronutrients?
Recommendation
Equity of consistent access to IV micronutrient preparations must become an international priority to support clinicians to provide safe PN and to be able to respond with clinically appropriate replacement therapies for patients with nonfunctioning guts.
Rationale
Individual IV forms of various micronutrients are not freely available in all countries and provide challenges in correcting abnormal values. 4 For instance, Zn, I, and Se are not available in parenteral form in many countries. Under these situations, clinicians have no alternative than to provide micronutrients enterally or orally in an attempt to meet patient requirements. This approach is fraught with risk as alteration of oral preparations (i.e., crushing tablets, piercing gel caps, and allowing contents to dissolve sublingually) is often required to allow administration, and when PN is indicated, case reports have demonstrated the lack of effectiveness of oral/enteral routes to adequately provide micronutrient requirements. 80 Equitable access to IV micronutrient preparations and individual micronutrients are required for safe clinical practice and must be an international priority to allow the safe and appropriate provision of PN.
Another issue is the intermittent shortages of micronutrients which can cause significant challenges for clinicians trying to provide safe and effective PN. North America has periodically experienced shortages of IV micronutrients over the last 30 years. 81 The reasons for this include regulatory issues, natural disasters, voluntary recalls, issues with raw materials, increase in demand, discontinuation, loss of manufacturing sites, and quality issues. 81 Mortality and morbidity associated with these shortages are acknowledged, with the most well described being complications of thiamin deficiency (fatal episodes of lactic acidosis, Wernicke's encephalopathy, and beriberi). 80, 82 However, a variety of other clinical manifestations have also been reported including Cu-deficient anemia and hyposelenemia. 83 AS-PEN has provided guidance on how to minimize clinical risk to patients in cases of periodic micronutrient shortage, 84, 85 and the FDA and other agencies are taking steps to improve the continuity of access of injectable drug products. 81, 86 While these steps are helpful, rectification of the underlying causes for the shortages are critical to safe provision of PN. Further discussion of the topic and resources to assist clinicians in navigating shortages of PN components have been reviewed elsewhere. 
The value of a multidisciplinary team-based approach to the provision of nutrition support including PN is well established, with demonstrated benefits including improved adherence to evidence-based practice, improved clinical outcomes, and financial savings. 87, 88 The clinician who initially enters a PN order, irrespective of the discipline (physician, nurse, dietitian, or pharmacist), is ultimately responsible for including orders for both MV and MTEs additives. Although regulations vary in geographic areas, in most countries a physician's order is required for PN. However, the physician may not have specific nutrition support training and may depend on the recommendations from members of a NST who have. When PN is compounded by pharmacists, yet another opportunity is available to assure addition of micronutrients. 89, 90 It is crucial that all NST members have adequate knowledge about the functions and requirements of micronutrients in patients receiving PN to avoid deficiencies and excess. 18, 67 In facilities where PN is compounded on site, the pharmacist is responsible for the PN admixtures preparation and should participate in the development and adherence to policies and procedures related to the compounding and delivery of safe and effective PN formulations. 67, 68, 91 Similarly, sound knowledge about Good Pharmaceutical Manufacturing Practice 78 in terms of standards, maintenance, and training is essential. 
Q11: How and when Should Micronutrient
Rationale
As the concurrent provision of MV and MTE supplementation with PN should meet micronutrient requirements, serum levels of micronutrients do not require routine monitoring in patients receiving short-term PN. 4, 20 When monitoring is required, laboratory testing to guide micronutrient provision include serum, plasma or whole blood levels, or enzyme function. 92 There is, however, a lack of universal consensus as to the optimal measures to use to assess status of specific micronutrients. 92 The availability and methods of testing vary widely between micronutrients and between regions, and clinicians are advised to liaise with their local laboratories and clinical experts for advice on what is available. In addition, micronutrient testing is often expensive 19, 20 and, therefore, judicious assessment and targeted monitoring is advised.
The decision to assess micronutrient status with biochemical measures may be considered in a number of clinical situations. 19, 20 19, 20, 66 r in cases of organ failure (liver or kidney), danger of toxicity necessitates monitoring. 4, 24 Renal function should be considered when vitamins and TEs are supplemented, 59 r in case of prolonged (>2 weeks) CRRT, 21 ,23 a monthly monitoring of hydrosoluble micronutrients may be considered. 93, 94 If micronutrients are included with macronutrient provision (i.e., each day PN is provided) and have been prescribed in consideration of the individual clinical requirements, the risk of developing micronutrient complications is low, and isolated micronutrient monitoring may be of limited value in otherwise stable patients in the acute setting. 19, 20 Therefore, careful consideration of the clinical significance of micronutrient testing needs to be considered in the acutely unwell patient, and routine measurement of serum vitamin levels is not usually recommended in critical care. 4 If micronutrient testing is considered to be appropriate, it should always be done in conjunction with a concurrent CRP level to allow interpretation 19, 20 (refer to question 4 and Table 2 ). Similarly, the time elapsed from the last provision of IV micronutrient infusion to the timing of the sample collection should be considered in the interpretation of results. It is not possible to provide a definite time period, since the infusion of micronutrients are sometimes done simultaneous to PN (in which case there is no time lapse) or the infusion can be separate from PN and given over 6 h. In the latter case, a time lapse of 2 h can be implemented before blood sampling. Ideally samples should be obtained after the longest possible break from PN/IV micronutrient infusion.
The AuSPEN Trace element and Vitamin Guidelines provide an outline of clinical considerations for when and how to biochemically assess individual micronutrients in the setting of PN. 19, 20 62 have produced evidence-based documents that provide recommendations regarding micronutrient practice in the context of PN. Guidelines addressing PN micronutrient provision highlight the need to provide micronutrients daily together with PN and individualization of micronutrient requirements and monitoring in long-term PN. Consensus recommendations for routine micronutrient administration via PN formulations from our group are provided in Table 5 and are largely consistent with previous recommendations.
Due to the essential role of micronutrients in metabolism, micronutrients should be provided daily in conjunction with PN to prevent the development of deficiency. Contemporary commercial MV and MTE preparations currently available meet the recommendations for most patient groups and should be used as a first-line provision. Consideration of additional replacement requirements may also be indicated in some clinical situations.
While there are some minor differences between these international guidelines owing to variation in methodology in the development process, clinical focus of guidelines, and/or regional vulnerability with regard to specific micronutrient deficiency, they all agree in principle on key overarching factors: a. Micronutrients are essential components of PN, without which the nutrition provided is metabolically incomplete. As such they should be provided from day 1 of PN commencement until PN cessation. b. Micronutrient prescription should be individualized to the clinical requirement of the patient. c. Micronutrient status should be monitored in longterm PN patients at baseline and 6-to 12-month intervals thereafter. 20, 62 At risk patients may be monitored at the discretion of the overseeing clinicians.
Toxicity due to increased administration of fat-soluble vitamins can occur. While adverse effects have not been observed with enteral provision of up 10 times the DRI for fat-soluble vitamins (which also applies to 10 times PN-RD), 100 times the DRI for water-soluble vitamins (or PN-RD), and 10-15 times the DRI for TEs, resolution of micronutrient derangements can be resolved with more modest replacement in the majority of clinical cases. Doses provided at significantly higher than routine maintenance doses outlined in the consensus recommendations should be considered as a short-term intervention, the results of which should be monitored. 4 Additional vitamin E is added to PN formulations containing high quantities of polyunsaturated fatty acids to combat lipid peroxidation and thus may incidentally provide adequate amounts to meet physiological requirements without further supplementation. 20 Clinicians, therefore, need to be familiar as to whether the routine addition of vitamin E to PN formulations occurs during compounding in their local setting.
Additional considerations around individual micronutrients such as supplementation dosages, conditions requiring additional levels, dangers of toxicity, and monitoring guidelines are discussed in Osland et al. 19 
Providing routine doses of Fe is standard practice among patients with intestinal failure or with very limited oral Fe absorption capacity (e.g., due to extensive resection of the upper GIT), as this element is essential. However, the optimal IV maintenance Fe regimen in the absence of anemia associated with chronic kidney disease (e.g., short bowel syndrome, bariatric surgery) warrants further investigations. It must be noted that IV Fe administration bypasses the normal regulatory mechanism of Fe bioavailability and homeostasis in the GIT. Since the daily turnover of Fe is low in most patients without anemia or chronic bleeding, oversupply of IV Fe risks causing Fe overload, increased oxidative stress, and infectious complications. Determining additional requirements in critically ill patients is difficult as inflammation alters Fe regulation and affects the accuracy of its laboratory assessments (e.g. ferritin). The prevalence of real Fe deficiency on ICU discharge, distinct from the inflammation sequestration issue, is elevated. A recent study based on hepcidin-assisted deficiency diagnosis showed it to be present in over 30% of patients. It contributes significantly to fatigue observed after discharge. 95 Recently, a better understanding of Fe metabolism has shown that blood hepcidin may assist in diagnosing Fe deficiency in the presence of inflammation 96 and is currently under investigation. 97 The benefits of short-term IV supplementation (0.5-1 g for a few days) in reducing transfusion requirement have not yet been proven, 98 but the trials have shown no increase in infectious complications, 98, 99 which were previously considered a prohibitive risk. It is, therefore, prudent to provide Fe to critically ill patients only in cases of proven Fe deficiency (which is best defined by hepcidin levels) 96 and not routinely. 99 Copper and Mn are excreted in the bile. In patients on long-term PN with hepatic failure, it is prudent to limit these TEs prior to obtaining serum levels. In addition, there are cases of Mn toxicity reported in long-term PN patients with magnetic resonance imaging of the brain showing Mn deposition in the basal ganglia (Mn encephalopathy). 100 This can be associated with neuropsychiatric symptoms and parkinsonism, 101 which can be reversed upon removing Mn from PN. 102 The newer commercial MTE available in some parts of the world have lower amounts of Mn compared with previous solutions, and this needs to be considered.
Patients with renal failure are at potential risk of vitamin A toxicity due to reduced excretion. 63 In case of prolonged PN, both excessive and insufficient levels may be observed, which may justify dosing vitamin A in plasma on an annual or biannual frequency. 
Q14: Are
Rationale
For a detailed review of refeeding syndrome, see Boateng et al. 103 Thiamin administration should be provided as a loading dose (300 mg/day IV) prior to nutrition commencement, followed by a maintenance dose of 100 mg/day (IV or oral) during nutrition to avoid deficiency complications developing. Broader MV and MTE supplementation should also be considered due to the risk of broad micronutrient vulnerability in patients at risk of refeeding, and concurrent micronutrient supplementation is essential in those receiving PN. Hypersensitivity reactions to PN are uncommon. However, case reports have identified the components thiamin, vitamin B complex, vitamin K, and magnesium sulfate as likely causes of hypersensitivity reactions. Polyoxyethylated fatty acid derivatives, similar to Cremophor EL, can also be found as a vehicle for fat-soluble vitamins leading to C activation-related pseudoallergy (CARPA). In addition, the inactive component, polysorbate, is believed to be a primary cause of hypersensitivity. Other case reports have identified the lipid emulsion component as the causative agent. 104 The option in these cases with regard to vitamins (not TE) might be to resort to modular assembly of a panel of vitamins, which conforms to patient's requirements if using singleentity products in lieu of commercial bundled micronutrient products. But there are currently no studies available. When vitamins or TEs cannot be added to PN for hypersensitivity reasons, it can be given enterally in situations where the GI tract is accessible and at least partly functional. 105 
Conclusion and call to action
This expert consensus paper has sought to highlight the importance of micronutrient provision as an integral daily part of safe and responsible PN provision. It has also attempted to translate the intent of the existing guidelines available as they pertain to micronutrient provision in a range of PN patient populations into practical terms. It is our hope that this will assist with the adoption of evidence-based recommendations irrespective of the level of experience of the clinician providing the PN intervention.
In terms of advocacy, there are a number of calls to action we wish to highlight. These affect the international nutrition community, the organizations they exist in, and the industries that support them.
1. The recognition that micronutrients must be provided daily from the commencement of PN macronutrients to provide safe and complete nutrition and that failure to do so will pose nutrition risk. Delays to micronutrient commencement, their voluntary omission or partial provision is unacceptable practice that must be abandoned, and any additional cost considerations must be considered as inclusive of the PN provision. 2. The acceptance that PN is not the only indication to prescribe IV micronutrients. There are other high-risk groups (e.g., inadequate enteral intake, excessive losses) that also necessitate additional micronutrients. 3. The imperative of having required IV micronutrient preparations-in individual or MV/MTE preparations-available within all markets in which PN is provided, and in consistent supply, cannot be understated as an essential element to the safe provision of PN. Steps must be taken to resolve the current discrepancies of regional access and inconsistency in supply. 4. Coupled with adequate supply of IV micronutrient preparations, it is important to ensure that the available products comply with the evidence-based recommendations in terms of composition. 5. More research should be conducted on the following: (i) method of administration of PN micronutrients, (ii) current situation with TE contamination in current compounding methods, (iii) compatibility and stability of micronutrients, especially TE solutions, (iv) multiple MN requirements in patients with special needs such as in the ICU, (v) development of affordable assays to determine multiple micronutrient levels. 6 . Commitment to provide advanced nutrition support training for clinicians to promote and deliver safe PN practice.
Ultimately micronutrients need to be understood as a critical component to nutrition provision and PN provided without them pose a considerable risk to nutrition status.
